Personalized Medicine

From Reactive Medicine to Proactive Medicine -- Transition of “Blockbuster” to “Stratified medicine” has begun with the aim of “Personalizing” therapeutics. Understanding the working of our genetic profiles will help in the development of “Individualized Medicine”, thereby expediting disease recovery and prognosis.

Comprehensive knowledge of genetics combined with phenotypic attributes can used to develop clinically significant Biomarkers -- for patient stratification, early detection of disease disposition, drug reclamation and new drug development.

Advancement in genomic technologies has raised the hope of Personalized Medicine -- giving access to a plethora of genetic information. Geschickten is working with deep focus to make Personalized Medicine a reality -- exploiting OMICS knowledge for discovery of sequence based differences, SNPs /InDels, gene expression profiles etc.

Geschickten works with Research organization, Pharmaceutical companies and Healthcare providers in identifying clinically significant Biomarkers that can be used for disease development, drug responsiveness or drug toxicity, drug reclamation, and patient stratification -- facilitating a more targeted approach to disease management.

For more information please write to This e-mail address is being protected from spambots. You need JavaScript enabled to view it.